Scarica l'app Stockscreener
9.41
1.47%
-0.14
Dopo l'orario di chiusura:
9.56
0.15
+1.59%
Precedente Chiudi:
$9.55
Aprire:
$9.71
Volume 24 ore:
1.63M
Relative Volume:
0.87
Capitalizzazione di mercato:
$818.83M
Reddito:
-
Utile/perdita netta:
$-168.09M
Rapporto P/E:
-4.3364
EPS:
-2.17
Flusso di cassa netto:
$-138.01M
1 W Prestazione:
-8.95%
1M Prestazione:
-11.81%
6M Prestazione:
+52.76%
1 anno Prestazione:
+20.95%
Intervallo 1D:
$9.35
$9.72
Intervallo di 1 settimana:
$9.24
$10.43
Portata 52W:
$5.41
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Nome
Kura Oncology Inc
Settore
Industria
Telefono
(858) 500-8800
Indirizzo
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Confronta KURA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
9.41 | 831.02M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-04 | Iniziato | Guggenheim | Neutral |
| 2025-02-06 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-14 | Downgrade | Stifel | Buy → Hold |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-08-11 | Iniziato | BofA Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-05-17 | Iniziato | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2022-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Iniziato | Jefferies | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-11-05 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-11-09 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-13 | Ripresa | Leerink Partners | Outperform |
| 2016-01-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-30 | Iniziato | Oppenheimer | Outperform |
| 2015-12-16 | Iniziato | Citigroup | Buy |
Mostra tutto
Kura Oncology Inc Borsa (KURA) Ultime notizie
Can Kura Oncology Inc. stock sustain institutional interestJuly 2025 Selloffs & Daily Entry Point Trade Alerts - ulpravda.ru
Rate Cut: Will Kura Oncology Inc. stock see insider buyingEarnings Summary Report & Consistent Return Strategy Ideas - ulpravda.ru
Is Kura Oncology Inc. stock affected by interest rate hikesGap Down & Community Verified Trade Signals - ulpravda.ru
Aug Intraday: Is Kura Oncology Inc. stock affected by interest rate hikesWeekly Stock Analysis & Verified Swing Trading Watchlist - ulpravda.ru
Research Analysts Set Expectations for Kura Oncology FY2030 Earnings - MarketBeat
Kura Oncology (NASDAQ:KURA) Stock Price Down 6.1%Here's Why - MarketBeat
Kura Oncology reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Kura Oncology (KURA) Grants Stock Options to New Employees - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Discipline and Rules-Based Execution in KURA Response - Stock Traders Daily
What analysts say about Kura Oncology Inc stockGeopolitical Risk Analysis & Affordable Trading Portfolio - earlytimes.in
Is Kura Oncology Inc a good long term investmentPrice-to-Book Ratio Updates & Maximize Gains Professionally - earlytimes.in
Kura Oncology Stock: Biotech Battleground With High Hopes And Higher Volatility - AD HOC NEWS
Jim Cramer calls Kura speculative but says "It's one of the stronger ones I've seen in a very long time" - MSN
Kura Oncology rises following Jim Cramer comments - MSN
(KURA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Jim Cramer Calls Kura Speculative But Says "It's One of the Stronger Ones I've Seen in a Very Long Time" - Finviz
Kura Oncology shows market leadership with jump to 93 RS rating - MSN
Kura Oncology (STU:KUR) EV-to-FCF : 3.00 (As of Dec. 23, 2025) - GuruFocus
Kura Oncology completes first U.S. commercial sale of KOMZIFTI - MSN
7 Stocks That Were on Jim Cramer’s Radar - Insider Monkey
Kura Oncology (KURA) Shares Surge After FDA Approval and Cramer Endorsement - GuruFocus
Kura Oncology (NASDAQ:KURA) Shares Gap UpHere's Why - MarketBeat
Kura Oncology (STU:KUR) EV-to-OCF : 2.87 (As of Dec. 22, 2025) - GuruFocus
Jim Cramer Discusses Kura Oncology as a Speculative Bet - Finviz
Kura Oncology (HAM:KUR) EV-to-OCF : 2.87 (As of Dec. 21, 2025) - GuruFocus
Jim Cramer discusses Kura Oncology as a speculative bet - MSN
Kura Oncology, Inc. $KURA Stock Position Lifted by Assenagon Asset Management S.A. - MarketBeat
Jim Cramer’s Latest Insights on These 13 Stocks - Insider Monkey
How the Narrative Surrounding Kura Oncology Is Changing After Komzifti Approval - Yahoo Finance
KURA (Kura Oncology) EV-to-OCF : 3.72 (As of Dec. 20, 2025) - GuruFocus
Francis Burrows Sells 23,726 Shares of Kura Oncology (NASDAQ:KURA) Stock - MarketBeat
Kura Oncology Chief Scientific Officer Sells Shares - TradingView — Track All Markets
Why analysts upgrade Kura Oncology Inc. stockWeekly Gains Summary & Daily Volume Surge Trade Alerts - DonanımHaber
Will Kura Oncology Inc. stock see insider buyingJuly 2025 PreEarnings & Low Risk High Win Rate Picks - DonanımHaber
Officer Burrows Files To Sell 23,726 Of Kura Oncology Inc [KURA] - TradingView — Track All Markets
Kura Oncology (NASDAQ:KURA) Shares Down 3.5%Here's Why - MarketBeat
Kura Oncology (KURA) Gains Momentum as Barclays Sees Significant Potential in Ziftomenib Approval - Finviz
Kura Oncology (KURA) gains momentum as Barclays sees significant potential in Ziftomenib approval - MSN
Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AMLSlideshow (NASDAQ:KURA) 2025-12-15 - Seeking Alpha
20 Stocks That Will Double in 2026 - Insider Monkey
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Is Kura Oncology Stock Built to Withstand More Downside? - Trefis
EcoR1 Capital LLC Boosts Stock Position in Kura Oncology, Inc. $KURA - MarketBeat
(KURA) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Kura Oncology, Inc. $KURA Shares Sold by Armistice Capital LLC - MarketBeat
Kura Oncology, Kyowa Kirin reveal Komsifti combo data for AML - MSN
Insider Sell: Faheem Hasnain Sells 10,000 Shares of Kura Oncology Inc (KURA) - GuruFocus
Kura Oncology Director Sells 10,000 Shares - TradingView — Track All Markets
Dir Hasnain Sells 10,000 ($109.8K) Of Kura Oncology Inc [KURA] - TradingView — Track All Markets
Kura Oncology Inc Azioni (KURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Kura Oncology Inc Azioni (KURA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Burrows Francis | Chief Scientific Officer |
Dec 18 '25 |
Sale |
9.78 |
23,726 |
231,931 |
33,735 |
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):